---
schema_version: "secwatch.filing_event.v1"
accession: "0001370053-23-000054"
form_type: "8-K"
ticker: "ANAB"
cik: "0001370053"
company_name: "ANAPTYSBIO, INC"
filed_at: "2023-10-10T23:59:59+00:00"
generated_at: "2026-06-10T02:06:25.230180+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# AnaptysBio reports positive Phase 3 GEMINI-1 trial for imsidolimab in GPP; 53.3% vs 13.3% placebo at Week 4

## Summary
- 53.3% of imsidolimab-treated patients achieved GPPPGA 0/1 at Week 4 vs 13.3% placebo (p=0.0131).
- No SAEs or severe AEs in imsidolimab-treated patients; low infection rate vs placebo.
- Only 3.3% had detectable non-neutralizing ADA.
- Plans to file BLA with FDA by Q3 2024 and out-license imsidolimab in 2024.
- Comprehensive data from GEMINI-1 and top-line GEMINI-2 expected H2 2024.

## SEC filing metadata
- accession: 0001370053-23-000054
- form_type: 8-K
- ticker: ANAB
- cik: 0001370053
- company_name: ANAPTYSBIO, INC
- filed_at: 2023-10-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1370053/000137005323000054/0001370053-23-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1370053/000137005323000054/anab-20231009.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001370053-23-000054
- JSON: https://secwatch.observer/filing/0001370053-23-000054.json
- Plain text: https://secwatch.observer/filing/0001370053-23-000054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.